|
1
|
Neurochemical, electrophysiological and pharmacological profiles of the selective inhibitor of the glycine transporter-1 SSR504734, a potential new type of antipsychotic.
|
Neuropsychopharmacology
|
2005
|
1.24
|
|
2
|
SSR180711, a novel selective alpha7 nicotinic receptor partial agonist: (1) binding and functional profile.
|
Neuropsychopharmacology
|
2006
|
1.14
|
|
3
|
Stimulation of the beta3-Adrenoceptor as a novel treatment strategy for anxiety and depressive disorders.
|
Neuropsychopharmacology
|
2007
|
1.08
|
|
4
|
SL651498, a GABAA receptor agonist with subtype-selective efficacy, as a potential treatment for generalized anxiety disorder and muscle spasms.
|
CNS Drug Rev
|
2003
|
0.89
|
|
5
|
Further evidence for the sleep-promoting effects of 5-HT₂A receptor antagonists and demonstration of synergistic effects with the hypnotic, zolpidem in rats.
|
Neuropharmacology
|
2013
|
0.84
|
|
6
|
SSR181507, a dopamine D(2) receptor antagonist and 5-HT(1A) receptor agonist. I: Neurochemical and electrophysiological profile.
|
Neuropsychopharmacology
|
2003
|
0.81
|
|
7
|
SSR181507, a dopamine D2 receptor antagonist and 5-HT1A receptor agonist. II: Behavioral profile predictive of an atypical antipsychotic activity.
|
Neuropsychopharmacology
|
2003
|
0.79
|